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Abstract
Wharton’s jelly mesenchymal stromal cells (WJ-MSCs) have been recently exploited as a feeder layer in coculture systems to
expand umbilical cord blood–hematopoietic stem/progenitor cells (UCB-HSPCs). Here, we investigated the role of WJ-MSCs
in supporting ex vivo UCB-HSPC expansion either when cultured in direct contact (DC) with WJ-MSCs or separated by a
transwell system or in the presence of WJ-MSC–conditioned medium. We found, in short-term culture, a greater degree of
expansion of UCB-CD34þ cells in a DC system (15.7+ 4.1-fold increase) with respect to the other conditions. Moreover, in
DC, we evidenced two different CD34þ cell populations (one floating and one adherent to WJ-MSCs) with different phe-
notypic and functional characteristics. Both multipotent CD34þ/CD38 and lineage-committed CD34þ/CD38þ hemato-
poietic progenitors were expanded in a DC system. The former were significantly more represented in the adherent cell
fraction than in the floating one (18.7+ 11.2% vs. 9.7+ 7.9% over the total CD34þ cells). Short-term colony forming unit
(CFU) assays showed that HSPCs adherent to the stromal layer were able to generate a higher frequency of immature
colonies (CFU-granulocyte/macrophage and burst-forming unit erythroid/large colonies) with respect to the floating cells. In
the attempt to identify molecules that may play a role in supporting the observed ex vivo HSPC growth, we performed
secretome analyses. We found a number of proteins involved in the HSPC homing, self-renewal, and differentiation in all
tested conditions. It is important to note that a set of sixteen proteins, which are only in part reported to be expressed in any
hematopoietic niche, were exclusively found in the DC system secretome. In conclusion, WJ-MSCs allowed a significant ex
vivo expansion of multipotent as well as committed HSPCs. This may be relevant for future clinical applications.
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Introduction
Unrelated umbilical cord blood (UCB) transplantation has
become one of the therapeutic options for pediatric patients
with hematological malignancies and various genetic
disorders1. The easy availability, the higher tolerance to
human leukocyte antigen (HLA)-mismatch, and the lower
incidence of graft-versus-host disease (GvHD) make UCB
an elective source of hematopoietic stem/progenitor cells
(HSPCs) for cell transplantation compared to bone marrow
(BM) and mobilized peripheral blood counterparts2. More
importantly, UCB-HSPCs have a higher frequency of pro-
genitors with greater clonogenic potential compared to adult
cells3. Nonetheless, the number of HSPCs derived from 1
UCB unit is often not sufficient for transplantation in adult
patients. In this regard, several attempts have been made to
expand HSPCs by using specific culture media, supplemen-
ted with different combinations of cytokines and chemical
compounds, and also by coculturing them with stromal fee-
der layers4. The long-term fate of transplanted HSPCs
greatly depends on their ability to adhere to the niche, with
subsequent regulation of self-renewal versus differentiation
states5. All of these functions are regulated by cues provided
in vivo by the hematopoietic niche cellular microenviron-
ment. The niche of BM has been studied in both human and
animal models6,7. Specialized cell types, such as mesenchy-
mal stromal cells (MSCs), endosteal and vascular cells, and
also pericytes, comprise the BM niche. Extracellular matrix
molecules are also key to maintain the balance between
HSPC self-renewal and differentiation8. Therefore, the
development of in vitro systems that could mimic the micro-
environment of a hematopoietic niche would improve the ex
vivo HSPC expansion strategies. Recently, numerous studies
have reported that MSCs from adult and perinatal sources
can be used as feeder layers to expand and maintain the
undifferentiated state of HSPCs9,10. Nevertheless, the cellu-
lar and molecular mechanisms mediating these interactions
are not fully elucidated. To date, few studies investigated
how the MSCs from different sources, influenced the quan-
tity and quality of expanded UCB-derived HSPCs in various
coculture systems. Furthermore, studies are lacking with
respect to a direct side-by-side comparison between cell–cell
contact, noncontact, and expansion in standardized media,
using UCB-derived HSPCs and MSCs. Wharton’s jelly (WJ)
is an attractive source of MSCs. It originates from the extra-
embryonic mesoderm (EM) that constitutes the mesenchy-
mal layer surrounding the amniotic cavity and yolk sac as
well as the stroma of umbilical cord (UC) and placenta11.
EM has been shown to support embryonic and fetal hemo-
poietic niches12. The WJ-derived MSCs (WJ-MSCs), iso-
lated from UC matrix, may be an ideal candidate for
creating an effective stromal feeder layer in coculture sys-
tems. These cells can be easily harvested and readily
expanded to reach a confluent monolayer in a short time13.
Furthermore, WJ-MSCs produce several cytokines involved
in the regulation of hematopoiesis, similarly to that observed
in BM-MSCs. Key examples are interleukin-6 (IL-6) stem cell
factor (SCF), Fms-related-tyrosine kinase-3 (Flt-3) ligand, and
growth factors such as macrophage colony–stimulating factor
(M-CSF), granulocyte colony–stimulating factor (G-CSF), and
granulocyte/macrophage (GM) colony–stimulating factor (GM-
CSF)14,15. It is important to note that the developmental history
ofWJ-MSCs further justifies a role for these cells in supporting
hematopoiesis by establishing a functional niche-like environ-
ment for UCB-HSPCs. Indeed, WJ is part of the extraembryo-
nicmesoderm, a tissue that arises early in the embryo liningand
is the very first hematopoietic niche (during the vitelline pri-
mitive hematopoiesis occurring in the wall of the yolk sac)16.
Further ahead in human development, umbilical vessels and
placenta have also been proposed as sites of hematopoiesis and
storage of embryonic definitive CD34þ cells; this led to the
concept of extraembryonic niches17. In this work, we investi-
gated the role of WJ-MSCs in supporting exvivoUCB-CD34þ
cell expansion. Cocultures were performed with CD34þ cells
cultured either directly on a WJ-MSC layer or in the presence
ofWJ-derived conditionedmedium (WJ-CM) or in a transwell
system (TS). Phenotypical and functional characterization of
the cultured CD34þ cells as well as systematical analysis of
secretomes were performed in order to assess the role of this
stromal cell population in the ex vivo expansion of HSPCs.
Materials and Methods
Isolation of WJ-MSCs
UCs (n ¼ 12) were obtained at the Villa Sofia-Cervello
Hospital, Palermo, Italy, after full-term births with written
informed consent from mothers and treated in accordance
with the tenets of the Declaration of Helsinki and local ethi-
cal regulations.
TheUCwas obtained at birth, after vaginal delivery or cesar-
ean section, and stored in cold Hank’s balanced salt solution
(HBSS) (Sigma-Aldrich, Milan, Italy), supplemented with 1
of antibiotic/antimycotic (penicillin/streptomycin, PAALabora-
tories, Pasching, Austria). UCs were processed for cell isolation
within12h frompartum.The isolationprocedurewasperformed
as reported previously18. Briefly, the collected UCs were cut
into small pieces (of about 1 to 1.5 cm length) and sectioned
longitudinally to expose the inner matrix, WJ, to the plastic
surface of 6-well plates (6-well tissue-culture treated,CytOne).
Each piece was completely covered with standard growth
medium composed of Dulbecco’s modified Eagle’s medium
(DMEM) lowglucose (Gibco,Milan, Italy) supplementedwith
10% heat inactivated fetal calf serum (FCS) (Gibco), 1 non-
essential aminoacids (Sigma-Aldrich), and1 penicillin/strep-
tomycin (PAA Laboratories). The cord fragments were left in
the culture medium for 15 d, with medium change every 2 d.
After 15 d of culture, the cord fragments were removed from
thewells, and cells attached to the plastic surfacewere cultured
until they reached confluence. The subsequently passaged cells
were collected by enzymatic treatment with 1XTrypLE Select
(Gibco) and replated at 10,000 cells/cm2.
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Phenotypical Characterization of WJ-MSCs
WJ-MSCs were routinely phenotyped at the first and fourth
passage by flow cytometry (FC-500 Beckman Coulter)
according to the manufacturer’s instructions. The antibodies
used were CD90-PC5, CD105-PC7, CD34-CD45-ECD (R
Phycoerythrin-Texas Red-X), HLA-DR-PE (Phycoerythrin),
all supplied by Beckman Coulter, and CD73-FITC, supplied
by BD Biosciences. Consistently, WJ-MSCs expressed the
expected mesenchymal markers CD73, CD90, and CD105
and were negative for the hematopoietic markers CD34,
CD45, and HLA-DR (data not shown). The ability of WJ-
MSCs to differentiate toward osteogenic, adipogenic, and
chondrogenic phenotypes was routinely assessed during cul-
ture passages as previously described19 (data not shown).
UCB-CD34þ Cell Immunoselection and Subtyping
UCB samples were collected at birth in isotonic saline solu-
tion supplemented with anticoagulant acid citrate dextrose
A. CD34þ cells were immunoselected using a CliniMACS
instrument (CD34 microbeads kit human, CliniMacs, Milte-
nyi Biotec) from the mononuclear cell fraction collected by
Ficoll-Paque Plus density 1.077 gradient (GE Healthcare,
Milan, Italy).
The absolute numbers and the frequencies of CD34þ cells
were measured in UCB samples at the time 0 and after 5 d of
culture by flow cytometry analysis according to ISHAGE
(International Society of Hematotherapy and Graft Engi-
neering) protocol with a single platform method (Stem Kit,
Beckman Coulter, Milan, Italy) that identifies the dual-
positive CD45þ/CD34þ cell population. To exclude dead
cells from the analysis, 7-aminoactinomycin D (7-AAD) was
used. The cells were cryopreserved in CS110 medium
(STEMCELL Technologies) until the next use.
Cell subtyping was performed by flow cytometry with a
4-color platform according to the manufacturer’s instruc-
tions. Cells were stained with the following monoclonal
antibodies or with the corresponding isotype controls:
fluorescein isothiocyanate (FITC)-conjugated CD45, ECD-
conjugated CD34, and PC5-conjugated CD38, supplied by
Beckman Coulter, and PE-conjugated CD133 (Miltenyi Bio-
tech). Data were analyzed using the Cxp Cytometer analysis
software and Kaluza software (Beckman Coulter).
Coculture of WJ-MSCs and UCB-derived CD34þ cells
All of the experiments were carried out in allogeneic sys-
tems. 5 104WJ-MSCs at the fourth passage were seeded in
each well of a 12-well plate (Costar, Corning) to reach a cell
confluence of 70% to 80%. Cell growth was arrested with
20 mg/mL mytomicin C (Sigma-Aldrich) for 2.5 h at 37 C in
the presence of 5% CO2. After incubation, the WJ-MSCs
were washed twice with phosphate buffered saline (PBS)
and cultured in standard growth medium for 24 h before
coculturing with CD34þ cells.
In all culture conditions, 2.5  104 CD34þ cells/mL/well
were grown in an animal component-free (ACF) medium
(Stem Span™ ACF STEMCELL Technologies, Inc.) formu-
lated for hematopoietic cell expansion, supplemented with a
1 cytokine cocktail (Stem Span™ CC110, STEMCELL
Technologies, Inc.), and contained recombinant stem cell
factor (SCF), Fms-related tyrosine kinase-3 ligand (Flt-3)
and thrombopoietin (TPO). In particular, CD34þ cells were
directly seeded on a WJ-MSC layer (DC system) or sepa-
rated from the stromal feeders by a transwell permeable
support (TS; 0,4 mm Polyester Membrane 12 mm Insert,
12-well Plate Tissue Culture Treated, Costar Corning) or
in the presence of WJ-CM or in ACF medium alone (expan-
sion medium [EM]). The evaluation of the CD34þ cell
expansion was reported as fold increase after 5 d of culture
with respect to time 0.
WJ-CM Preparation
WJ-MSCs at the fourth passage were used to produce a
conditioned medium. Cells were grown in ACF medium
until reaching a confluency of 70% to 80% and arrested
with 20 mg/mL mitomycin C for 2.5 h at 37 C in a 5%
CO2 atmosphere. After cytostatic treatment, cells were
washed twice with PBS and incubated for 48 h in ACF
medium, supplemented with a CC110 cytokine cocktail.
The medium was collected and centrifuged at 1,200 rpm
for 8 min to remove the cellular debris and stored at80 C
for the subsequent analyses.
Immunocytochemical (ICC) Analysis
After culturing, cells grown in chamber slides were washed
with PBS and fixed in methanol for 20 min at 20 C. Air-
dried slides were then stored at20 C until use. For the ICC
procedure, cells were permeabilized with 0.1% Triton X-100
in PBS (Sigma-Aldrich). After a subsequent rinse with PBS,
immunocytochemistry (ICC) was performed using the ICC/
IHC “Histostain Plus 3rd Gen IHC Detection” kit (Invitro-
gen). The primary antibodies used for this study were diluted
with saponin 0.1% in PBS 1 and they were Fibronectin
(Sigma-Aldrich), CD34 (Dako, Milan, Italy), and Vimentin
(Dako). Nuclear counterstaining was obtained using hema-
toxylin (Dako).
Colony Forming Unit (CFU) Assay
The ability of CD34þ cells to form colonies in short-term
assay after 5 d of culture in WJ-CM EM and DC conditions
was assessed: 1.5 103 CD34þ cells were plated in triplicate
in the complete methylcellulose medium (MethoCult H4434
Classic, STEMCELL Technologies, Inc.) in 35-mm culture
dishes and incubated at 37 C in 5% CO2 for 14 d.
Colonies were counted and analyzed for morphology
using an inverted microscope and a scoring grid. Colony
morphologies were classified as CFU-GM, burst-forming
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unit erythroid (BFU-E), colony forming unit granulocytes
(CFU-G), colony forming unit monocytes, and colony form-
ing unit granulocyte/erythroid/macrophage/megakaryocytes
(CFU-GEMM).
Statistical Analysis
All statistical analyses were done using GraphPad Prism
(version7.02; https://www.graphpad.com/scientific-soft
ware/prism/). Results are presented as mean + standard
deviation (SD). To test statistical significance, a paired para-
metric t-test was used. Results were considered significant
for P value <0.05.
Sample Preparation for Secretome Analyses
All media from different culture conditions were harvested,
centrifuged (1,100 rpm at 4 C for 5 min) and filtered
through a 0.22-mm filter (Millipore) to remove cells and
debris. The supernatants were dialyzed to remove and mini-
mize charged ions and salts for the subsequent mass spectro-
metry (MS). After the dialysis, the samples were lyophilized
and resuspended in ultrapure water in order to obtain a 100-
fold protein concentration.
In Solution Digestion
The digestion step was performed adding Trypsin/Lys-C
Mix (Promega) to 50 mg of proteins at a 25:1 protein:pro-
tease ratio (w/w), following the manufacturer’s instructions.
Peptides, obtained after the digestion, were concentrated and
desalted with Pierce C18 Spin Columns (Thermo Scientific).
Then the samples were lyophilized and suspended in an
appropriate buffer (0.1% formic acid) for subsequent
applications.
High-performance Liquid Chromatography (HPLC)
and Electrospray MS
Reversed-phase HPLC separation and online mass spectro-
metry detection (HPLC-MS/MS) were performed using an
UltiMate 3000 System (Dionex) combined with Linear Trap
Quadrupole (LTQ) Orbitrap XL™ Hybrid Ion Trap-orbitrap
Mass Spectrometer (Thermo Fisher, Milan, Italy) via elec-
trospray ionization (ESI) source. The chromatographic
separation was carried out on a Hypersil Gold C18 column
(15 cm  2.1 mm, 1.9 mm). Sequential elution of peptides
was accomplished using a flow rate of 50 mL min1 and a
linear gradient from 98% solution A (0.1% formic acid) to
98% of solution B (80% acetonitrile, 0.08% formic acid) in
120 min. The gradient elution program was as follows: 2 min
98:2, 4 min 87:13; 95 min gradient from 87:13 to 50:50, 104
min 2:98, 109 min 2:98, 110 min 98:2, and 120 min 98:2
(A:B, v/v). The column temperature was set at 25 C, and the
sample tray temperature was maintained at 4 C. For all
experiments, a sample volume of 4 mL was loaded. For MS
detection, the ESI source was operated in the positive mode
and run with Xcalibur version 2.0 software (Thermo Fisher).
High-purity nitrogen was used as the sheath, and the auxiliary
gas and high-purity helium was used as the collision gas.
Data Analysis
The raw data were processed using Proteome Discoverer
version 1.4 (Thermo Scientific). MS/MS spectra were
sequentially searched with SequestHT and MS Amanda,
both set against Homo sapiens database using the following
parameters: full trypsin digest with maximum 2 missed clea-
vages; fixed modification carbamidomethylation of cysteine
(þ57.021 Da); variable modification oxidation of methio-
nine (þ15.995 Da); and phosphorylation of tyrosine, serine,
and threonine (þ79.966 Da). Precursor mass tolerance was
10 ppm and fragment ion tolerance was 0.8 Da. Peptide
spectral matches were validated using percolator.
In Silico Analysis
In order to confirm the identified proteins, in silico analyses
were carried out using the online ExPASy Proteomics Server
(http://www.expasy.org) and the UniProt database (http://
www.uniprot.org). For functional analysis of the proteomics
data, the Database for Annotation, Visualization, and Inte-
grated Discovery (version 6.8, https://david.ncifcrf.gov/)
was applied.
Results
Phenotypic Characterization of WJ-MSCs and
UCB-CD34þ Cells
The MSC population derived from WJ was isolated by its
ability to migrate and adhere to a plastic surface. Cells were
subcultured for 4 passages prior to being used as feeders in
coculture system. The morphological and phenotypical anal-
yses, as well as the differentiative properties, were evaluated
at the first and fourth passage. During culture, WJ-MSCs
maintained the typical fibroblastoid morphology, with
cell–cell contacts highlighted by processes extending
between adjacent cells.
CD34þ cells from 12 UCB independent samples were
enriched for CD34þ cells by immune selection to reach a
purity of 90.2 + 3.7% with a recovery of 65 + 5%. The
selected CD34þ cell population was subtyped for the pres-
ence of 2 surface markers, CD133 and CD38, that identify
more primitive and committed hematopoietic progenitor
cells, respectively. The frequency of CD34þ/CD133þ cells
in the uncultured cell population was 90.2 + 5.8, and the
frequency of CD34þ/CD38 cells was 40 + 11%.
Phenotypic, functional, and proteomic analyses were per-
formed after 5 d of WJ-MSC/CD34þ cell coculture; in our
previous experiences, at this relatively short time of culture,
the frequency of CD34þ cells within the total expanded cell
population is only slightly decreased.
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UCB-CD34þ Cell Expansion in Different Culture
Systems
To investigate the role of WJ-MSCs to support in vitro
expansion of HSPCs, the UCB-CD34þ cells were cultured
either directly on WJ-MSC feeders (DC condition) or sepa-
rated from feeder cells by TS, or in presence of conditioned
medium derived from WJ-MSCs (WJ-CM), as well as in a
standard EM alone. First, we assessed that 2.5 104 cells/mL
was the optimal seeding concentration to favor the cell
expansion kinetic and that the presence of the 3 cytokines
(SCF, TPO, and flt-3) known to support hematopoietic stem
and progenitor cells was essential for cell growth in all tested
culture conditions (data not shown). After 5 d of culture, the
number of CD34þ cells significantly increased in all condi-
tions with respect to time 0 (P < 0.0001); in particular, we
observed a 15.7+ 4.1-fold increase in the DC system, 9.5+
3.3 in WJ-CM, 8.4+ 3.3 in EM, and 5+ 2.2 in TS (Fig. 1).
Notably, the DC system resulted in a superior expansion
with respect to all the other culture conditions (P 
0.001). At this time of culture, the frequency of CD34þ cells
over the total hematopoietic cell population decreased by
about 25% to 35% in the different culture conditions with
respect to the uncultured samples (Fig. 1). Analogue results
have already been reported in culture systems and expansion
media very close to the conditions that we used in our experi-
ments20. This result shows that a portion of CD34þ cells are
expanded while another portion of them differentiates.
The low expansion degree observed in TS was probably
influenced by a mechanical hindrance of TS per se. Prelim-
inary experiments (not shown) indicated that the TS is able
to expand CD34þ cells only at very low concentrations,
different from those used for this study.
In Vitro Interactions between CD34þ Cells and
WJ-MSCs in the DC System
By phase-contrast microscopy, we observed within the direct
coculture system that the expanded CD34þ cells localized in
2 distinct compartments: a floating cell population and
another one adherent to the WJ-MSCs. Figure 2 shows that
the majority of hematopoietic cells are floating in the
medium. These cells can be easily harvested by medium
aspiration. About one-third (36.9 + 7.1% of the total
expanded CD34þ cells in the DC condition) of the HSPCs
are tightly bound to the stromal feeder cell layer. These
adherent cells were harvested only after enzymatic treatment
that breaks cell–cell or cell–matrix interactions. In fact as
shown in Fig. 2, the adherent cells were either directly asso-
ciated with WJ-MSCs or with the extracellular matrix
(ECM) deposited by feeder cells. This is the first time that
such an observation was made in a coculture system with
WJ-MSCs as a feeder layer for UCB-HSPCs.
Immunocytochemistry analysis was performed to
demonstrate the expression and localization of different
molecules that mark specifically hematopoietic or stromal
cells (Fig. 3). CD34 antibody was used to stain the HSPCs,
showing the presence of the CD34þ cells over the WJ-
MSCs that were negative for this marker (Fig. 3A). Vimen-
tin, a typical cytoskeletal marker of MSCs, was localized in
both HSPCs and WJ-MSCs (Fig. 3B and C), confirming
literature data from our group and others18,21 HSPCs
showed pseudopodia-like protrusions indicating an active
migratory activity over the culture surface. (Fig. 3D), a
Fig. 1. The fold increase of expanded umbilical cord blood–CD34þ
cells after 5 d of culture in different conditions: direct contact (DC)
system, Wharton’s jelly mesenchymal stromal cells–conditioned
medium (WJ-CM), expansion medium (EM), and transwell system
(TS). This graph also reports the frequency of CD34þ cells after 5 d
of culture in all conditions. All results are presented as mean+ SD.
Fig. 2. Microscopical demonstration of the multiple ways of inter-
actions between Wharton’s jelly mesenchymal stromal cells (WJ-
MSCs) and CD34þ cells in the direct contact system. CD34þ cells
seeded on a layer of WJ-MSCs and cultured for 5 d expand their
numbers and establish different interactions with feeder cells
(A–D). Phase-contrast microscopy allows for detection of a float-
ing population that constitutes about two-thirds of the total
expanded cells (indicated by white arrows in all panels). An adher-
ent population is represented by cells which adhere to the feeder
cells or to the culture surface (indicated by black arrows in all
panels). Magnification: 200. Bar: 100 mm.
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Fig. 3. Microscopic demonstration of the expression of intracellular and extracellular molecules in the direct contact (DC) system. CD34þ cells
belonging to the adherent fraction can be easily visualized in areas aroundWharton’s jelly mesenchymal stromal cells (WJ-MSCs) as shown by
their staining for anti-CD34 antibody (A). (B, C) Vimentin stains both WJ-MSCs and hematopoietic stem/progenitor cells (HSPCs). Higher
magnification images (400, C) show the close association between theWJ-MSC feeder layer andHSPCs. Apart from interactingwithWJ-MSCs,
HSPCs clearly show arrangements directed by the extracellular fibronectin polymerized by WJ-MSCs. (D) Fibronectin antibody shows cyto-
plasmic stain inWJ-MSCs but not in HSPCs. The protein is polymerized in an extracellular network with fibers localized both at the periphery of
cells and on the culture surface. As indicated, HSPCs show pseudopodia-like protrusions (arrows) indicating a migratory activity over the vessel
surface, which is covered with fibronectin filaments. The inset shows a higher magnification view of the cellular protrusions. (E) Extracellular
fibronectin directs the adhesion of HSPCs (100). (F) Higher magnification of the panel E (200) showing nests of HSPCs localizing across
fibronectin extracellular fibers and at the periphery of WJ-MSCs. (G) High-power view (400) of panel F showing the interactions between
HSPCs and the surrounding fibronectin-rich microenvironment. (H) The peripheral positive fibronectin stain in some HSPCs (with absence of
cytoplasmic stain) suggesting a close receptor-mediated interaction.Magnifications: 100 (B, E), 200 (D, F), and 400 (A,C,G,H). Bar: 100mm.
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datum already reported in a similar coculture system where
CD34þ cells were cocultured with WJ-MSCs20. Fibronec-
tin was expressed exclusively by WJ-MSCs (Fig. 3D-H).
The cells showed an intense cytoplasmic staining according
to their ability to produce and polymerize extracellular
matrix molecules. Interestingly, fibronectin was localized
extracellularly both at the periphery of WJ-MSCs and over
the glass culture surface. This provided means for CD34þ
cells to attach firmly to both WJ-MSCs and the culture
slide. This is particularly evident in Fig. 3E-G showing that
the arrangement of CD34þ cells follows the direction of the
extracellular fibronectin fibers. High-power field images
(Fig. 3H) suggest a close association between extracellular
fibronectin and CD34þ cells, giving the impression of a
positive staining at the membrane of the cells, which is
however not matched by the expected cytoplasmic stain
of cells actively synthesizing the molecule. Therefore, this
suggests that CD34þ cells closely interact with fibronectin
via receptor-mediated interaction.
Subtyping of Expanded CD34þ Cells
The frequencies of CD34þ/CD133þ and CD34þ/CD38
subpopulations that identify early progenitor cells were mea-
sured in all culture conditions and within the 2 hematopoietic
cell fractions of the DC system. After 5 d of culture, the
frequency of CD34þ/CD133þ progenitor cells was slightly
decreased compared to the uncultured samples in all condi-
tions and also within the 2 cell populations of the DC system
(P  0.0377; Table 1).
Differences in the coexpression of the CD38 marker,
which discriminate committed (CD34þ/CD38þ) from multi-
potent (CD34þ/CD38) progenitors22, were observed
between CD34þ cells grown in direct contact with WJ-
MSCs and all the other conditions. In particular, the fre-
quency of the CD34þ/CD38 subpopulation over the total
CD34þ cells was significantly increased in both EM and TS
with respect to that of uncultured UCB-CD34þ cells. In
particular, we observed a 2-fold increase in both EM and
TS (P < 0.0001) and a 1.3-fold in WJ-CM (P ¼ 0.0074;
Table 1). Conversely, in the DC system, the frequency of
multipotent progenitor cells decreased in both floating and
adherent compartments when compared to the uncultured
cells (P  0.0003). This decline was observed to a lesser
extent in the adherent cell fraction (2-fold decrease) than in
the floating cells (Table 1). These results highlighted that the
cell–cell contact greatly favored the production of commit-
ted hematopoietic progenitors with respect to the other tested
culture conditions. Notably, in the DC condition, the CD34þ
cells adherent to the stromal layer comprised a higher per-
centage of early primitive cells when compared to the
respective floating compartment (18.7 + 11.2% vs. 9.7 +
7.9%, P < 0.0001). In terms of absolute numbers, the
CD34þ/CD38 early progenitors were found expanded in
the DC culture system after 5 d; in particular, we observed
a 2-fold increase in the floating cell population and a 3-fold
increase in the adherent one (data not shown).
Overall, these data highlighted that cell–cell contact pro-
moted both proliferation and differentiation of HSPCs
resembling the main features of a hematopoietic niche. Sim-
ilar results have been reported by Jing and colleagues who
performed cocultures of mobilized peripheral blood-derived
CD34þ cells over a feeder layer of BM-MSCs. The authors
suggested that the hematopoietic cells beneath MSCs fea-
tured the low proliferation rate and displayed the markers of
an immature phenotype23.
Table 1. Frequency of Primitive CD34þ Subtypes over the Total CD34þ Cells.
Uncultured Cells
DC System
WJ-CM TS EMFloating Cells Adherent Cells
CD34þ/CD38, % 40.2 + 9.2 9.7 + 7.9 18.7 + 11.2 52.9 + 9.0 81.9 + 5.8 89.2 + 4.8
CD34þ/CD133þ, % 90.2 + 5.8 84.4 + 6.6 84.0 + 4.8 82.9 + 8.5 79.9 + 9.2 79.9 + 8.1
Note: Results are reported as mean + SD. DC ¼ direct contact; WJ-CM ¼Wharton jelly–conditioned medium; TS ¼ transwell system; EM ¼ expansion
medium.
Table 2. Frequency of Colonies Generated from CD34þ Cells Cultured in Direct Contact System.
Colonies
DC System
Floating Cells Adherent Cells P Values
% CFU-GM þ BFU-E/total colonies 35.0 + 14 46.8 + 13.9 0.007
% CFU-GEMM/total colonies 0.5 + 0.5 3.5 + 1.3 0.0001
% BFU-E(L)/total BFU-E colonies 19.0 + 6.3 37.0 + 14.7 0.013
Note: Results are reported as mean+ SD. DC ¼ direct contact; CFU-GM ¼ colony forming units–granulocyte/macrophage; BFU-E ¼ burst-forming units–
erythroid; BFU-E(L) ¼ intermediate/large burst-forming units–erythroid; CFU-GEMM ¼ colony forming units–granulocyte/erythroid/macrophage/
megakaryocytes.
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Colony Forming Capacity of HSPCs Expanded in the
DC Condition
We assessed the ability of CD34þ progenitor cells localized
in the 2 compartments of the DC system to develop differ-
ent types of colonies in 6 of the total 12 UCB samples. A
higher proportion of primitive colonies, (CFU-GM) and
erythroid colonies (BFU-E), was developed from cells of
the adherent fraction (P value ¼ 0.007) compared to the
cells of the respective floating ones (Table 2). Moreover,
the most primitive colonies, GEMM colonies (CFU-
GEMM) even if represented at very low frequencies in
unmanipulated UCB samples (about 1% over the total colo-
nies developed), also exhibited a trend of increase in the
adherent cell fraction compared to the floating one (on
average 3.5% vs. 0.5%, respectively).
A further confirmation that adherent CD34þ cells are more
primitive HSPCs comes from the analysis of BFU-E colony
size. The frequency of intermediate/large BFU-E colonies
(that consisted of more than 7 clusters) over the total BFU-
E colonies was significantly increased in the hematopoietic
cells plated from the CD34þ cells adherent to the WJ-MSCs
with respect to the floating cell fraction (37.0+ 14.7 vs. 19.0
+ 6.3, respectively, P ¼ 0.013; Table 2).
Proteomic Analysis of Conditioned Media
In order to identify molecular players involved in the cross-
talk between CD34þ cells and WJ-MSCs, we analyzed the
secretome of different culture media by HPLC-MS/MS. Nota-
bly, in our analyses, we did not consider the presence of SCF
and FLT-3 ligand, since these cytokines are components of the
EM used in all conditions. We identified 166 proteins in the
EM, 154 proteins in the upper compartment of the transwell
coculture system (TS1), 114 proteins in the lower compart-
ment of the transwell coculture system (TS2), 133 proteins in
the DC, and 105 proteins in the WJ-CM. The TS medium was
analyzed both in the upper and lower compartments in order to
discriminate molecules that may be distinctively produced by
hematopoietic and/or stromal cells, therefore not passing
through the pores of the transwell PETmembrane for different
reasons such as extracellular deposition.
Since our experiments showed that the CD34þ cells can
establish different interactions with WJ-MSCs (i.e., the
presence of an adherent and a floating cell fraction within
DC), we focused our analysis on extracellular proteins that
can recreate in vitro a microenvironment similar to that of
a hematopoietic niche. We highlighted the presence of 30
extracellular/exosomal or membrane proteins, listed in
Table 3, and we performed a comparative analysis among
tested culture conditions to investigate the expression dif-
ferences24–68. Interestingly, in the DC secretome, we iden-
tified a set of 16 exclusively expressed proteins. Only
some of them were already described in any of the known
hematopoietic niches, either prenatal or adult, with most
data coming from studies on BM.
Structural molecules with cytoadhesive roles such as col-
lagens, namely, types I, III, and VI, were detected in the
secretome of the WJ-MSCs in the 2 coculture conditions
(DC and TS2). Confirming the data of ICC analyses shown
before, here for the first time, we report the presence of
fibronectin as player in cross talk with HSPCs. In fact, secre-
tomic data have allowed detection of fibronectin expression
in WJ-CM, DC, and TS2.
Interestingly, specifically in the DC system, we found for
the first time the expression of Frem3 a molecule involved in
cell adhesion reported to be expressed in BM36. We also
detected in the DC, WJ-CM, TS2 systems, tissue inhibitor
of metalloproteinases-1 (TIMP-1) a protein directly involved
in the finely regulated remodeling of the BM extracellular
matrix49 (Table 3).
We detected for the first time specifically in the DC con-
dition the a-fetoprotein, well known to be expressed in in
vivo prenatal hematopoietic niches.
Here, we report for the first time the presence of lacto-
transferrin (iron binding and multifunction protein) in the
DC system.
Serine carboxypeptidase-1 (SCPEP1) is a secreted serine
protease which has been implicated in monopoiesis44. Inter-
estingly, in our system, this molecule was expressed only in
the DC secretome. We are the first to show SCPEP1 expres-
sion by human WJ-MSCs because only one literature report
(to the best of our knowledge) demonstrated its expression in
porcine WJ-MSCs45.
Wnt-4 and Wnt-6 are part of the recently discovered
noncanonical Wnt-Ca2þ pathway which is active in
hematopoiesis55. No data are present in literature on the
expression of these molecules in coculture systems with
WJ-MSCs. Here, we demonstrated that Wnt-4 was specif-
ically found in TS1, while Wnt-6 was present in the DC
secretome. Noteworthy in the DC system, we identified the
presence of Notch2. Wnt and Notch signaling are integrated
and are selectively active in regulating hemopoiesis and
have been implicated in erithropoiesis63 and in supporting
ex vivo expansion of HSPCs. Transforming growth factor-
beta (TGF-b) pathways are involved in the regulation of the
HSPC homeostasis. Interestingly, we found the TGF-b
induced protein H3 (BIGH3) in the DC and WJ-CM
secretomes.
Moreover, we detected the secreted molecule a-2 HS gly-
coprotein (Fetuin A) in all the tested coculture conditions.
Importantly, this molecule binds several growth factors (such
as TGF-b) regulating their access to surface receptors27. Finally,
CD109 is a glycosylphosphatidylinositol-anchoredglycoprotein
that binds theTGF-b receptor.Here,we showed thatCD109was
detected only in the DC culture system (Table 3).
Discussion
In the present article, we investigated howWJ-MSCs or their
soluble factors influenced the kinetics of UCB-HSPC expan-
sion and which type of hematopoietic subpopulations was
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amplified in vitro. Our experiments were performed in a
relatively short time to avoid extensive manipulation of
HSPCs in order to set ex vivo expansion protocols suitable
for future clinical applications.
Our data showed that the DC system sustained a greater
CD34þ cell expansion rate with respect to the other tested
conditions. Moreover, we here report for the first time that
i. CD34þ cells interacted with WJ-MSCs in different
fashions allowing the detection of a floating and an
adherent fraction;
ii. WJ-MSCs polymerized an intricate fibronectin-rich
network, directing the arrangement of the CD34þ
cells and providing a microenvironment which
favored the interaction between the 2 cell types;
iii. the DC system recapitulates some functional aspects
of a hematopoietic niche. In fact, it is able to expand
a component of primitive cells, with phenotypic fea-
tures typical of long-term repopulating cells, and
also to greatly increase the number of lineage-
committed shorter-term repopulating cells.
These results are relevant for the outcome of hematopoietic
stem cell transplantation.
In fact, the more primitive cells have been linked to the
long-term engraftment of a transplant, while an expansion
product with more mature committed progenitors and
mature cells will be needed to facilitate engraftment to a
clinically relevant degree69.
In addition, adherent CD34þ cells were able to develop a
higher frequency of primitive colonies, CFU-GM and large
BFU-E, and also of the most primitive CFU-GEMM in com-
parison to the floating cells.
Relevant to these results, we observed a rare hematopoie-
tic stem cell (HSC) population (identified by other authors70
for the coexpression of CD34/CD90 and CD49f and the lack
of CD38 and CD45RA) that was more represented in the
adherent cell fraction (unpublished observation).
It is important to note that we showed that the WJ-CM
also promoted the ex vivo expansion of CD34þ cells, even if
to a lesser extent than the cell–cell contact system. In par-
ticular, WJ-CM sustained the growth of multipotent hema-
topoietic progenitors. This finding can be relevant in clinical
translation. Further experiments will be needed to better
scale up and define this system.
Overall, these functional data revealed that both
WJ-MSCs and their soluble factors may be important
tools to increase the number of UCB-CD34þ cells in ex
vivo systems.
WJ-MSCs physiologically contribute to create the micro-
environments that sustain hematopoiesis during the embryo-
nic and fetal period of life. A better characterization of
factors produced by WJ-MSCs in the different culture sys-
tems may therefore provide important insights on the future
expansion strategies employed for UCB-derived CD34þ
cells.
The secretomic analysis of the different tested culture
conditions revealed the presence of specific molecules that
may be potentially be involved in the observed supporting
effects on CD34þ cell expansion. The polymerization of an
active extracellular matrix already suggested by fibronectin
immunolocalization is further validated by the identification
of several other adhesion molecules, such as collagens type
I, III, and VI, which were consistently found in the DC
condition. These molecules together with fibronectin and
SPARC are known to be part of the BM and UC and pla-
cental hematopoietic niches29,31–33,46,47.
We also found proteins expressed in prenatal hematopoie-
tic sites such as yolk sac and fetal liver and involved in
hematopoiesis, namely alpha-fetoprotein (AFP) and lacto-
trasferrin. It is also important to note that it has been reported
that MSC-derived AFP prevents apoptosis of HSPCs by
cooperating with SCF26.
Wnt signaling pathway molecules were also found in our
cocolture system. In hematopoietic cells, Wnt proteins may
function as proliferation-inducing growth factors, and also
affect cell-fate decisions, similar to true morphogens in other
systems54,55.
Interestingly, a number of TGF-b interacting molecules
(BIGH3, Fetuin A, and CD109) were found in the secre-
tomes of our coculture system. Multiple reports have shown
that TGF-b members regulate tissue homeostasis and regen-
eration. With respect to hematopoiesis, TGF-b plays an
important role in regulating HSPC behavior, particularly
regarding quiescence and self-renewal71. BIGH3 has been
reported to be part of the hematopoietic (BM) niche by med-
iating the adhesion of HSPCs, which can bind this molecule
both via integrin-dependent and integrin-independent adhe-
sion51. As a modulator of HSPC adhesion and migration,
competing for fibronectin binding sites in adhesion assays,
BIGH3 may be essential to loosen the contacts of HSCs with
their originating niche, rendering them susceptible to polar-
ization and subsequent egress52.
Fetuin A is known to be expressed in embryonic/fetal
tissues (such as fetal liver). In addition to its known role in
binding TGF-b receptor, CD109 was reported as part of the
exosomal fraction. Moreover, a secreted furin-cleaved
CD109 fragment can modulate TGF-b signaling in adjacent
cells58. It is particularly intriguing that negative regulators of
TGF-b activity, such as fetuin A and CD109, are expressed
in this in vitro expansion system and specifically in the DC
culture. Therefore, present data suggest that regulation of the
TGF-b pathways may in part explain the results obtained so
far in our DC system.
Conclusion
Our results showed that both WJ-MSCs and their condi-
tioned medium are capable of sustaining in vitro hemato-
poiesis and can be used as a tool to promote HSPC
expansion for clinical applications. We also provided insights
on the possible mechanisms behind the hematopoiesis support
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function of WJ-MSCs. Interestingly, the secretomic analysis
showed that the molecules expressed in the DC system reca-
pitulated a functional niche-like hematopoietic microenviron-
ment, a finding further supported by morphological analyses
reported here. We highlighted that the DC system specifically
provides the expansion of either multipotent or committed
progenitor cells, both essential for the outcome of HSPC
transplantation. To this end, clinical trials already demon-
strated that co-transplantation of UCB-HSPCs and WJ-
MSCs generates a superior graft with respect to UCB alone,
as reviewed in Reference 9. Further studies are needed to
better delineate the roles of the molecular players that we
identified in our experiments.
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